Literature DB >> 11772419

Goals of statin therapy: three viewpoints.

Gilbert R Thompson1, Christopher J Packard, Neil J Stone.   

Abstract

The "lipid hypothesis" is now universally recognized as a law. Few issues in medicine are as completely resolved as the question of whether reducing serum cholesterol increases longevity. However, there are a few questions that remain, and the most important uncertainty is to what extent cholesterol should be reduced. The medical community, in partnership with government and industry, has contributed many excellent trials demonstrating the effects in patients with elevated cholesterol (above the mean). Where should our goal of therapy be? Until data is available from several large, ongoing trials, we do not have a final answer. We asked three investigators, Drs. Gilbert Thompson, Christopher Packard, and Neil Stone, who have all been integrally involved in the accumulation of our present database, to argue three different possible answers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11772419     DOI: 10.1007/s11883-002-0059-6

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  31 in total

1.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

2.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

3.  Statin trials and goals of cholesterol-lowering therapy.

Authors:  S M Grundy
Journal:  Circulation       Date:  1998-04-21       Impact factor: 29.690

4.  Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting.

Authors:  A M Gotto; S M Grundy
Journal:  Circulation       Date:  1999-03-02       Impact factor: 29.690

5.  Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering?

Authors:  P Cullen; G Assmann
Journal:  Am J Cardiol       Date:  1997-11-15       Impact factor: 2.778

6.  Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Sharrett; C M Ballantyne; S A Coady; G Heiss; P D Sorlie; D Catellier; W Patsch
Journal:  Circulation       Date:  2001-09-04       Impact factor: 29.690

7.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

8.  The emergence of triglycerides as a significant independent risk factor in coronary artery disease.

Authors:  G Assmann; H Schulte; H Funke; A von Eckardstein
Journal:  Eur Heart J       Date:  1998-10       Impact factor: 29.983

9.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  2 in total

1.  The quest for immunotherapy in atherosclerosis: CANTOS study, interleukin-1β and vascular inflammation.

Authors:  Valmore Bermúdez; Joselyn Rojas-Quintero; Manuel Velasco
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 2.  Atherosclerotic Cardiovascular Disease Risk and Evidence-based Management of Cholesterol.

Authors:  Satyajeet Roy
Journal:  N Am J Med Sci       Date:  2014-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.